David is head of the corporate practice of the Belgium office.
With over 15 years of extensive industry experience, David specialises in every aspect of corporate transactional work, such as public and private M&A, venture capital transactions, public offerings and general company law. A significant proportion of David’s work focuses on the life sciences and biotech sectors.
He has advised a wide range of leading Belgian companies and foreign multinationals, with a particular emphasis on modern technology companies. Recent work highlights include advising TiGenix on its NASDAQ IPO, advising the group Onepoint on its public takeover bid on Vision IT Group and a series of financing and capital market transactions for leading Belgian biotech companies.
He obtained his law degree from the KU Leuven (2001) and an LL.M at King’s College London (2003). Before joining Osborne Clarke in 2013, David spent nearly 10 years at Linklaters. He regularly publishes updates on company law in a leading Belgian legal journal.
MEET DAVID HAEX AT #KFG2018
David Haex will be presenting a satellite workshop, together with Jasper Evers:
"Pitfalls and Opportunities in the US for the EU Life Sciences companies"
Europe and Belgium in particular has a lot to offer in terms of life sciences technology. However, in order to get this technology to patients on a global scale, life sciences companies need to be able to scale-up in terms of speed/financing/partnerships and market access. Currently US companies have the advantages of a large home market and abundance of available venture capital. Therefore it can make sense for EU companies to cross the atlantic and go to the US to create equal opportunities. David and Jasper will speak on what it takes to go there, pitfalls and opportunities from a strategic, financial and legal perspective.